Summary
This 8-K filing from Quest Diagnostics Inc. announces a change in executive compensation arrangements, specifically the inclusion of Manuel O. Mendez, Senior Vice President and Chief Commercial Officer, as a Schedule B Participant in the company's Executive Officer Severance Plan. This update to the severance plan, effective November 19, 2019, signifies a formalization of Mendez's eligibility for benefits under this specific plan, which is common for key executives. Investors should note that this filing primarily concerns executive compensation and does not appear to disclose material financial results or significant operational changes at this time.
Key Highlights
- 1Manuel O. Mendez, SVP and Chief Commercial Officer, has been added to the Executive Officer Severance Plan.
- 2This change became effective on November 19, 2019.
- 3Mendez is now a 'Schedule B Participant' under the plan.
- 4The filing references an 'Amended and Restated Quest Diagnostics Incorporated Executive Officer Severance Plan' as Exhibit 10.1.
- 5The purpose of the filing is to report this change in executive officer compensatory arrangements.
Frequently Asked Questions
The primary purpose of this 8-K filing is to inform investors about a change in an executive officer's compensatory arrangement, specifically the inclusion of Manuel O. Mendez in the company's Executive Officer Severance Plan.
Manuel O. Mendez is the Senior Vice President and Chief Commercial Officer of Quest Diagnostics Inc.
The Executive Officer Severance Plan is a company-provided benefit that outlines the terms and conditions under which certain key executives would receive severance pay and benefits upon termination of employment under specific circumstances, as detailed in the plan document.
No, this 8-K filing does not contain any new financial results or performance data for Quest Diagnostics. It is solely focused on reporting a change in executive compensation.